{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-24-094349","form_type":"8-K","ticker":"INM","cik":"0001728328","company_name":"InMed Pharmaceuticals Inc.","filed_at":"2024-11-05T23:59:59+00:00","discovered_at":"2026-05-14T18:03:09.383061+00:00","generated_at":"2026-05-30T05:25:15.962032+00:00","sec_items":["3.01","7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"InMed Pharmaceuticals granted Nasdaq exception until Dec 2; plans 1-for-20 reverse stock split","bullets":["Nasdaq Panel grants InMed exception to Dec 2, 2024 to show $1 bid price compliance for 10 consecutive trading days.","Board approved 1-for-20 reverse stock split on Oct 29, 2024; shares would reduce from ~14.36M to ~718k.","Reverse split requires no shareholder action; fractional shares not issued; trading symbol INM unchanged.","Company must evidence compliance by Dec 2; no assurance of regaining compliance by that date."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-24-094349","json":"https://secwatch.observer/filing/0001213900-24-094349.json","markdown":"https://secwatch.observer/filing/0001213900-24-094349.md","text":"https://secwatch.observer/filing/0001213900-24-094349.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1728328/000121390024094349/0001213900-24-094349-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1728328/000121390024094349/ea0220029-8k_inmed.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T05:25:15.962032+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}